
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 11, 2024

PepGen Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-41374
(Commission File Number)

85-3819886
(IRS Employer
Identification No.)

321 Harrison Avenue
8th Floor
Boston, Massachusetts
(Address of Principal Executive Offices)

02118
(Zip Code)

Registrant's Telephone Number, Including Area Code: (781) 797-0979

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value \$0.0001 per share	PEPG	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events.

On June 11, 2024, PepGen Inc. (the “Company”) announced the promotions of Michelle Mellion, M.D., to Chief Medical Officer and Hayley Parker, Ph.D., to Senior Vice President, Global Regulatory Affairs. A copy of the press release issued in connection with this announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

Exhibit Number	Description
99.1	Press release issued by PepGen Inc. on June 11, 2024
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PEPGEN INC.

Date: June 11, 2024

By: /s/ Noel Donnelly
Noel Donnelly, Chief Financial Officer



PepGen Announces Executive Team Promotions

Michelle Mellion, M.D., promoted to Chief Medical Officer

Hayley Parker, Ph.D., promoted to Senior Vice President, Global Regulatory Affairs

BOSTON, June 11, 2024 -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced two executive team promotions effective immediately: Michelle Mellion, M.D., to Chief Medical Officer and Hayley Parker, Ph.D., to Senior Vice President, Global Regulatory Affairs.

"I am excited to announce the well-deserved promotions of Michelle and Hayley, a true testament to their hard work, dedication, and leadership. Since joining PepGen, they have played integral roles in driving both our clinical and regulatory strategies, advancing our pipeline of differentiated oligonucleotides, and paving a path for future commercialization," said James McArthur, Ph.D., President and CEO of PepGen. "As we continue to execute on our goals and prepare for preliminary data readouts and additional trial initiations, I look forward to working with our incredible team to take the vital next steps in bringing our potentially disease-modifying therapies to people living with rare muscle disorders."

Michelle Mellion, M.D., promoted to Chief Medical Officer, joined PepGen as Senior Vice President, Head of Clinical Development and has been instrumental in overseeing the Company's global clinical development strategy, as well as advancing the Company's neuromuscular programs into the clinic. She was also recently appointed to Medical Advisor of the FSHD Society. Previously, Dr. Mellion served in roles of increasing responsibility at Fulcrum Therapeutics, where she led the design and implementation of Phase I/II/III clinical trials for the company's novel treatment of facioscapulohumeral muscular dystrophy. In parallel, she worked as an Attending Physician affiliated with Tufts Medical Center, specializing in Neurology as a member of their Pediatrics department. Earlier, Dr. Mellion held leadership roles at Vertex Pharmaceuticals and Biogen, as well as working as an Attending Neurologist in the Muscular Dystrophy Association (MDA) clinic and Attending Physician and Assistant Professor of Neurology at Alpert Medical School, Brown University. She completed her residency at Brown Medical School, received her M.D. from the Wake Forest University School of Medicine, and earned her B.A. in Molecular Biology from Colgate University.

Hayley Parker, Ph.D., promoted to Senior Vice President, Global Regulatory Affairs, joined PepGen as Vice President, Regulatory Affairs and has been pivotal in developing and executing the Company's global regulatory strategy and interactions with regulatory authorities. Previously, she served as Vice President, Regulatory Affairs at Scholar Rock, accountable for the global regulatory strategy for their lead neuromuscular program. Earlier, Dr. Parker gained experience in rare disease holding various leadership positions at Vertex Pharmaceuticals where, as part of the Regulatory Leadership team, she was Head of Global Labelling and global therapeutic strategic lead for early phase pain assets, and at Biogen working in rare diseases with high unmet medical need, such as Spinal Muscular Atrophy. She earned her Ph.D. in Molecular Biology and Respiratory Medicine at Imperial College, London, and her B.Sc. in Molecular Biology from the University of Hertfordshire.

About PepGen

PepGen Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen's Enhanced Delivery Oligonucleotide, or EDO, platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases.

Investor Contact

Noel Donnelly
Chief Financial Officer
ndonnelly@pepgen.com

Media Contact

Julia Deutsch
Lyra Strategic Advisory
Jdeutsch@lyraadvisory.com
